Artielle has recently completed double-blind, placebo-controlled, Phase I, dose escalation study of the safety of a single intravenous (IV) dose of RTL1000 in MS patients.
The drug was administered to six cohorts (escalating doses ranging from 2mg to 200mg) and all subjects were followed over 28 days. The primary endpoint was met and a maximum tolerated dose established.
Artielle is currently planning its Phase I/II program in MS and other indications.
